Corstasis Therapeutics, a biopharmaceutical company providing outpatient therapeutic options for patients with cardiovascular and renal disease, announced that the U.S. Food and Drug Administration (FDA) has approved Enbumyst (bumetanide nasal spray). Enbumyst is indicated to treat edema associated with congestive heart failure (CHF), hepatic and renal disease, including nephrotic syndrome in adults. Enbumyst demonstrated rapid absorption and predictable diuretic response in clinical stud...